IPP Bureau

Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma
Formation Bio snaps up global rights to next-gen CNS TYK2 inhibitor from Lynk Pharma

By IPP Bureau - December 12, 2025

LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure

New oral SERD from Roche delivers significant survival edge in early breast cancer
New oral SERD from Roche delivers significant survival edge in early breast cancer

By IPP Bureau - December 12, 2025

At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival

Lupin Manufacturing Solutions partners with PolyPeptide to scale global peptide supply chain
Lupin Manufacturing Solutions partners with PolyPeptide to scale global peptide supply chain

By IPP Bureau - December 12, 2025

This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets

Shilpa Medicare receives initial authorization for Rotigotine transdermal patch from Europe
Shilpa Medicare receives initial authorization for Rotigotine transdermal patch from Europe

By IPP Bureau - December 12, 2025

This is the first approval of a prescription transdermal dosage Form in the European markets from this facility

Granules India receives official 2025 CDP rating
Granules India receives official 2025 CDP rating

By IPP Bureau - December 12, 2025

The company had achieved the highest "A" rating in Climate Change

Dr. Reddy's Laboratories announces SBTi targets
Dr. Reddy's Laboratories announces SBTi targets

By IPP Bureau - December 12, 2025

Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045

Senores Pharmaceuticals launches of Deferiprone Tablets USP, 500 mg & 1000 mg
Senores Pharmaceuticals launches of Deferiprone Tablets USP, 500 mg & 1000 mg

By IPP Bureau - December 12, 2025

The product will be marketed by Dr. Reddy's Laboratories Inc.

Granules Life Sciences facility receives EIR from USFDA
Granules Life Sciences facility receives EIR from USFDA

By IPP Bureau - December 12, 2025

This approval confirms the facility's compliance with FDA quality standards and regulatory requirements

Apitoria Pharma receives 3 observations from USFDA for Unit-V
Apitoria Pharma receives 3 observations from USFDA for Unit-V

By IPP Bureau - December 12, 2025

The company will respond to the US FDA within the stipulated timelines

Teva files FDA application for once-monthly schizophrenia injection
Teva files FDA application for once-monthly schizophrenia injection

By IPP Bureau - December 11, 2025

The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time

Lilly drug cuts risk of disease progression or death by 80% in trial
Lilly drug cuts risk of disease progression or death by 80% in trial

By IPP Bureau - December 11, 2025

The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study

BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy
BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy

By IPP Bureau - December 11, 2025

The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first

Roche secures CE mark for groundbreaking Vaginitis test that promises accurate diagnosis
Roche secures CE mark for groundbreaking Vaginitis test that promises accurate diagnosis

By IPP Bureau - December 11, 2025

Roche says its new assay “resolves this challenge by delivering accurate and specific results

Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients
Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients

By IPP Bureau - December 11, 2025

The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies

Bristol Myers Squibb unveils breakthrough Lymphoma data
Bristol Myers Squibb unveils breakthrough Lymphoma data

By IPP Bureau - December 11, 2025

Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas

Latest Stories

Interviews

Packaging